



## Clearbridge Biophotonics inks sub-license deal with computational microscopy company, Scpio Labs Ltd.

- Deal validates the market resonance and technical utility of the Fourier Ptychographic Microscopy (“FPM”) patent estate licensed exclusively by Clearbridge Biophotonics Pte Ltd (“Clearbridge Biophotonics”)

**SINGAPORE – 2 October 2018 – Clearbridge Health Limited (“Clearbridge” or the “Company” and together with its subsidiaries, the “Group”) (明策集团),** said that its subsidiary, Clearbridge Biophotonics, has entered into a sub-license agreement with Scpio Labs Ltd. (“Scpio”), to provide access to the FPM patent estate from California Institute of Technology.

Scpio, founded in 2015 by CEO Itai Hayut and Erez Na’aman, develops next-generation digital microscopes, based on computational imaging breakthroughs, as well as a suite of dedicated image analysis tools. Their products enable dramatic clinical and research improvements in diverse areas such as cancer, hematology and cytology, while powering further innovation in areas such as academic research and drug discovery.

Clearbridge Biophotonics is leveraging on the FPM technology to develop first-in-class, massively-parallel microscopy, (i.e. all 96-wells of a 96-well microplate simultaneously) at an acceptable market price point, enabling high-content, high-throughput, real-time monitoring of the initial phases (first 1-30 minutes) of cellular responses to provide presently unattainable insights into drug discovery. Further applications of the technology, that enable wide field-of-view all in resolution, optical lens aberration correction, and computational refocusing, include clinical diagnostics, cell counting and digital pathology.

**Mr Jeremy Yee (余斌), Executive Director and Chief Executive Officer of Clearbridge,** said: *“We are pleased to see the continued development and advance of the FPM technology from Clearbridge Biophotonics and now the signing of this sub-license agreement with Scpio. This collaboration is a testament to the utility of the technology and our focus to monetise our technology assets.”*



**Itai Hayut, CEO & Founder of Scpio**, said: “We are excited to collaborate with Clearbridge Biophotonics and to gain access to the FPM patent estate, complementary to our broad IP portfolio, as we are preparing to launch our computational microscopy platform, able to deliver the highest image quality while digitizing and analyzing microscopy slides”.

-- END --

#### **About Clearbridge Health Limited**

Clearbridge Health Limited is a healthcare company with a focus on the delivery of precision medicine in Asia. Its business comprises laboratory testing services, medical clinics/centres and strategic equity participation in complementary precision medical technology companies. Through the delivery of precision medicine in Asia, it seeks to empower clinicians and healthcare professionals to make more reliable and accurate diagnoses, provide insights to disease management, and tailor personalised prevention and timely treatment programmes for patients.

For more information, please visit us at [www.clearbridgehealth.com](http://www.clearbridgehealth.com).

---

*Issued by and on behalf of Clearbridge Health Limited*

#### **August Consulting**

Tel: +65 6733 8873

Silvia Heng, [silviaheng@august.com.sg](mailto:silviaheng@august.com.sg)

Wrisney Tan, [wrisneytan@august.com.sg](mailto:wrisneytan@august.com.sg)

Zavier Ong, [zavierong@august.com.sg](mailto:zavierong@august.com.sg)

*This press release has been prepared by the Company and its contents have been reviewed by the Company's sponsor, United Overseas Bank Limited (the “Sponsor”), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the “SGX-ST”).*

*The Sponsor has not independently verified the contents of this press release. This press release has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.*

*The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.*